TeneligliptinThird Party Manufacturing in India

Teneligliptin works by competitively inhibiting the dipeptidyl peptidase-4 enzyme, which rapidly degrades the incretin hormones GLP-1 and GIP. It inhibits this target to help the body extend the active physiological half-life of circulating incretins, thereby stimulating glucose-dependent insulin secretion from pancreatic beta cells while suppressing inappropriate glucagon release from alpha cells. Unlike sulfonylureas, its mechanism is strictly glucose-dependent, minimizing the clinical risks of sudden hypoglycemia. It is highly effective and well-tolerated for type-2 diabetes management.

Therapeutic Uses

• Type 2 Diabetes Mellitus: Functions as an effective adjunct to diet and exercise to optimize glycemic control in adults.
• Postprandial Hyperglycemia: Specifically targets and lowers blood glucose spikes that occur immediately following food intake.
• Combination Glycemic Care: Integrates smoothly alongside Metformin or other oral antidiabetic agents when single therapies prove insufficient.

Why Manufacturers Choose Teneligliptin

Teneligliptin third party manufacturing in India has witnessed explosive volume growth due to its broad renal safety profile, allowing use in patients with kidney impairment without heavy dose adjustments. Producing high-quality, stable antidiabetic formulations requires strict adherence to granular content uniformity. Our partner production lines are fully accredited under WHO-GMP standards, utilizing automated validation protocols to deliver cost-effective, high-volume batches for domestic and international markets.